Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy.

IF 4.7 2区医学 Q1 CLINICAL NEUROLOGY

Therapeutic Advances in Neurological Disorders Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI:10.1177/17562864241276204

Afsaneh Shirani, Nil Saez-Calveras, Jack P Antel, Moein Yaqubi, Wayne Moore, Amy L Brewster, Olaf Stuve

{"title":"Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy.","authors":"Afsaneh Shirani, Nil Saez-Calveras, Jack P Antel, Moein Yaqubi, Wayne Moore, Amy L Brewster, Olaf Stuve","doi":"10.1177/17562864241276204","DOIUrl":null,"url":null,"abstract":"Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.Objectives: To explore the association of MS disease-modifying therapies (DMTs) and FDA-approved Bruton tyrosine kinase inhibitors (for lymphocytic malignancies) with the occurrence of epilepsy using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.Design: Secondary analysis of the FAERS database.Methods: We conducted a disproportionality analysis of FAERS between 2003-Q4 and 2023-Q3. MS DMTs and the Bruton tyrosine kinase inhibitor, ibrutinib, were included in the analysis. An inverse association was defined by a 95% confidence interval (CI) upper limit of reporting odds ratio (ROR) <1.Results: We found an inverse association of ibrutinib, ocrelizumab, ofatumumab, rituximab, and teriflunomide with epilepsy. The strongest inverse association was seen with ibrutinib (ROR: 0.338; 95% CI: 0.218-0.524).Conclusion: Our findings suggest the possibility of considering these medications for repurposing opportunities in epilepsy and support a potential pathogenic role of leukocyte subsets in seizure perpetuation.","PeriodicalId":22980,"journal":{"name":"Therapeutic Advances in Neurological Disorders","volume":"17 ","pages":"17562864241276204"},"PeriodicalIF":4.7000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Neurological Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864241276204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.

Objectives: To explore the association of MS disease-modifying therapies (DMTs) and FDA-approved Bruton tyrosine kinase inhibitors (for lymphocytic malignancies) with the occurrence of epilepsy using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Design: Secondary analysis of the FAERS database.

Methods: We conducted a disproportionality analysis of FAERS between 2003-Q4 and 2023-Q3. MS DMTs and the Bruton tyrosine kinase inhibitor, ibrutinib, were included in the analysis. An inverse association was defined by a 95% confidence interval (CI) upper limit of reporting odds ratio (ROR) <1.

Results: We found an inverse association of ibrutinib, ocrelizumab, ofatumumab, rituximab, and teriflunomide with epilepsy. The strongest inverse association was seen with ibrutinib (ROR: 0.338; 95% CI: 0.218-0.524).

Conclusion: Our findings suggest the possibility of considering these medications for repurposing opportunities in epilepsy and support a potential pathogenic role of leukocyte subsets in seizure perpetuation.

查看原文本刊更多论文

探索多发性硬化症疾病修饰疗法和 BTK 抑制剂与癫痫的关联。

背景：多种证据表明炎症在癫痫中的作用。多发性硬化症（MS）患者的癫痫发作率是年龄匹配的普通人群的两到三倍：目的：利用美国食品药品管理局不良事件报告系统（FAERS）数据库，探讨多发性硬化症改变病情疗法（DMT）和美国食品药品管理局批准的布鲁顿酪氨酸激酶抑制剂（用于淋巴细胞恶性肿瘤）与癫痫发生的关系：方法：对 FAERS 数据库进行二次分析：我们对 2003 年第四季度至 2023 年第三季度的 FAERS 数据库进行了比例失调分析。分析包括 MS DMTs 和布鲁顿酪氨酸激酶抑制剂伊布替尼。报告几率比（ROR）的 95% 置信区间（CI）上限定义了逆相关性结果：我们发现伊布替尼、奥克利珠单抗、ofatumumab、利妥昔单抗和特立氟胺与癫痫呈反向关联。伊布替尼的逆相关性最强（ROR：0.338；95% CI：0.218-0.524）：我们的研究结果表明，可以考虑将这些药物用于癫痫的再治疗，并支持白细胞亚群在癫痫持续发作中的潜在致病作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Neurological Disorders CLINICAL NEUROLOGY-

CiteScore

8.30

自引率

1.70%

发文量

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Neurological Disorders is a peer-reviewed, open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of neurology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in neurology, providing a forum in print and online for publishing the highest quality articles in this area.